Bristol-Myers Squibb Company (BMY) Holdings Trimmed by Tdam USA Inc.
Tdam USA Inc. cut its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 103,153 shares of the biopharmaceutical company’s stock after selling 1,090 shares during the period. Tdam USA Inc.’s holdings in Bristol-Myers Squibb were worth $5,758,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of BMY. Toronto Dominion Bank lifted its holdings in shares of Bristol-Myers Squibb by 54.0% in the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after purchasing an additional 162,884 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 1.9% in the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after purchasing an additional 3,833 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $6,150,000. Meridian Management Co. lifted its holdings in shares of Bristol-Myers Squibb by 1.5% in the first quarter. Meridian Management Co. now owns 51,770 shares of the biopharmaceutical company’s stock valued at $2,815,000 after purchasing an additional 770 shares in the last quarter. Finally, Tobam lifted its holdings in shares of Bristol-Myers Squibb by 124.5% in the first quarter. Tobam now owns 793,714 shares of the biopharmaceutical company’s stock valued at $43,163,000 after purchasing an additional 440,170 shares in the last quarter. Hedge funds and other institutional investors own 68.84% of the company’s stock.
BMY has been the topic of a number of research reports. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Cowen and Company set a $65.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 10th. Jefferies Group LLC restated a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. Finally, Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price target on the stock in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Buy” and an average price target of $63.21.
Bristol-Myers Squibb Company (NYSE:BMY) opened at 65.29 on Monday. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10. The firm’s 50-day moving average price is $62.78 and its 200-day moving average price is $56.98. The firm has a market cap of $107.07 billion, a P/E ratio of 23.85 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter last year, the firm earned $0.69 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, equities research analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.39%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.
In other news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at approximately $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is owned by company insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.